Radius Announces FDA Acceptance for Filing of New Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis

WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS ), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA) for abaloparatide–SC has been accepted for filing by the U.S. Food and Drug Administration (FDA).  The acceptance of the NDA reflects the FDA’s determination that the application is sufficiently complete to permit a substantive review.

“The FDA’s acceptance for filing of our abaloparatide-SC NDA is a major milestone for Radius and we look forward to continuing to work with the FDA as they review our application,” said Robert E. Ward, President and CEO of Radius Health. “Given the high unmet medical need in osteoporosis, we believe that abaloparatide-SC, if approved, has the potential to become a promising new treatment option for the approximately 10 million postmenopausal women with osteoporosis, many of whom remain untreated.”

The NDA is supported by data from the entire abaloparatide-SC development program, including the results from the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women with osteoporosis and the first six months of the ACTIVExtend trial in 1,139 of the ACTIVE participants.  Positive results for abaloparatide-SC treatment groups from the ACTIVE and ACTIVExtend trials have met the primary and secondary endpoints essential for submission of the NDA, including the primary endpoint of reduction of vertebral fractures as well as key endpoints of reduction of nonvertebral, clinical, and major osteoporotic fractures.  In these and the other trials submitted in the NDA, abaloparatide-SC administered at a dose of 80 mcg daily was generally safe and well tolerated in postmenopausal women with osteoporosis.

As previously reported, Radius submitted a Centralised Marketing Authorisation Application (MAA) for abaloparatide-SC in the European Union on November 17, 2015, which was validated by the European Medicines Agency (EMA) in December 2015, and is currently undergoing active regulatory assessment by the Committee for Medicinal Products for Human Use of the EMA (CHMP).  The EMA has granted Radius an additional 3-month extension to the procedural timetable for response in the ongoing MAA assessment. As a result of this extension to the procedural timetable, the Company now anticipates that the CHMP may adopt an Opinion regarding the MAA in late 2016 or in 2017.

Abaloparatide-SC is an investigational treatment for postmenopausal women with osteoporosis and its safety and efficacy have not been established.

About Radius Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) has been accepted for filing by the FDA.  The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.

About Abaloparatide Abaloparatide is an investigational therapy for the potential treatment of postmenopausal women with osteoporosis. Abaloparatide is a novel synthetic peptide that engages the parathyroid hormone receptor (PTH1 receptor) and was selected for clinical development based on its favorable bone building activity.

Abaloparatide has completed Phase 3 development for potential use as a daily self-administered injection (abaloparatide-SC). Radius’ NDA for abaloparatide-SC was accepted for filing by the US Food and Drug Administration in May 2016, for the treatment of postmenopausal women with osteoporosis. In December 2015, Radius's MAA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis was validated by the European Medicines Agency for commencement of Centralised assessment by the Committee for Medicinal Products for Human Use (CHMP). The MAA is currently undergoing regulatory review by the CHMP.

Radius also is developing abaloparatide-transdermal (abaloparatide-TD) based on 3M's patented Microstructured Transdermal System technology for potential use as a short wear-time transdermal patch.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding expectations for abaloparatide-SC, including without limitation, expectations regarding the clinical significance of clinical trial data for abaloparatide-SC, the potential medical benefit of treatment with abaloparatide-SC for postmenopausal women with osteoporosis, the progress of abaloparatide-SC in the regulatory process with the FDA and the EMA, and the potential clinical uses for the abaloparatide transdermal patch, RAD1901 and RAD140.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risk that the results of clinical trials of abaloparatide-SC will not meet regulatory requirements for approval or that regulatory authorities may require additional data or further studies; our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval or be successfully commercialized; the risk that results of clinical trials of abaloparatide-SC and of our other product candidates may not support product claims, even if approved; failure to achieve market acceptance of abaloparatide-SC, if approved; the availability of coverage and reimbursement for abaloparatide-SC, if approved; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; failure to establish an effective process for distribution of abaloparatide-SC; and the other important factors discussed under the caption "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 25, 2016, and in our other reports filed with the SEC, that could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release.  While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact: Barbara Ryan Email: bryan@radiuspharm.com Phone: 203-274-2825 Media Contact: Lori Gorski Email: Lgorski@radiuspharm.com Phone: 617-551-4096

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 87

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
NCPDP Elevates J.W. Hill to President & COO Role

Updated Category News Views 46

Plotting the Course for NCPDP's Future Today's shakeup at the NCPDP has got the sector's ears perked. For those who don't speak in acronym soup all day—NCPDP stands for National Council for Prescription Drug Programs. They're the brains behind many crucial healthcare standards, improving information flow around meds, supplies, and services. Now, they're taking bold...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 104

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 103

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 173

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 102

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 65

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Organizations: RockDove Solutions on Crisis Communication

Updated Category News Views 111

Understanding the Importance of Crisis Communication Plans In today's fast-paced world, effective crisis communication is more critical than ever for businesses. Surprisingly, fewer than half of U.S. companies have formal crisis communication strategies in place. This statistic highlights a significant gap in business continuity planning, where communication often...

Continue Reading
Hafnia Limited Reports Strong Earnings for Q3 2024 Period

Updated Category News Views 83

Hafnia Limited Reports Strong Earnings for Q3 2024 Period Hafnia Limited (“Hafnia” or “the Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a premier product tanker company with an extensive and modern fleet exceeding 130 vessels, has recently reported promising financial results for the three and nine months ended September 30, 2024. Key...

Continue Reading
Recent Shareholding Changes at Irish Continental Group PLC

Updated Category News Views 138

Understanding Director and PDMR Shareholding Notifications In the world of corporate governance, transparency plays a crucial role in maintaining trust, particularly when it comes to senior management and directors. Recent notifications reveal key transactions involving persons discharging managerial responsibilities (PDMRs) at Irish Continental Group plc. Overview of...

Continue Reading
Experience the Summer Vibes at Coastal Mississippi Events

Updated Category News Views 220

Summer Events in Coastal Mississippi Come Play Coastal all summer long with seafood feasts, fireworks, car shows, and more! Ready to turn up the fun this summer? Coastal Mississippi is bringing a thrilling lineup of unforgettable events, all set against the backdrop of 62 miles of beautiful shoreline. From fresh seafood to electrifying fireworks, sensational car shows,...

Continue Reading
GUNNAR Optiks and 2K Games Unveil Exciting New Glasses

Updated Category News Views 197

GUNNAR Optiks Partners with 2K Games for New Glasses GUNNAR Optiks, a frontrunner in combating digital eye strain and a pioneer in blue light blocking eyewear, has teamed up with 2K Games to introduce an exciting new collection inspired by the much-anticipated Borderlands 4. This striking collection unveils its first eyewear style, aptly named the Ripper, marking the...

Continue Reading